… RET alteration (ie, fusions or mutations) were eligible. Here, we report the efficacy and safety
of selpercatinib in patients with RET fusion… patients with RET fusion–positive lung cancer, 8 …

… , whole-transcriptome analysis of other organs has not identified RET fusions in cancers
outside the lung. Therefore, RET fusion may occur mainly in LADC and papillary thyroid cancer. …

… relationship between RET fusion–positive lung adenocarcinomas and the solid-predominant
subtype. Another study of ALK rearrangements in lung adenocarcinomas suggested a …

… then, RET fusions have been reported in ∼1%–2% of lung cancer, predominantly … lung
cancers harboring RET fusions are sensitive to tyrosine kinase inhibitors (TKIs) with anti-RET …

… RET within the tumor. In this study, two additional KIF5B‐RET fusions were identified among
20 lung … More recently, a CCDC6‐RET fusion was identified in the human lung cancer cell …

… RET-fusion positive non-small cell lung cancer, RET-fusion … cancer, or RET-mutation positive
meduallary thyroid cancer. This … the RET- cohort if there was no evidence of a RET fusion in …

… This comprehensive review covers a range of topics in RET fusion-positive NSCLC that
have direct relevance to cancer care. Clinically relevant background information on RET …

… RET-altered solid tumours, including RET fusion-positive NSCLC, and the second study to
report on outcomes with a selective RET … activity in patients with RET fusion–positive NSCLC, …

… and kinase fusion genes now form a group of relevant targetable oncogenes in lung cancer.
… during Transfection fusions, the third kinase fusion gene in lung cancer, is briefly described. …

… and selective RET inhibitors and the various diagnostic techniques for RET gene fusion. In
… unsolved issues on treatment for RET fusion-positive lung cancer and future developments. …